McDougall, C., McKay, G. A. and Fisher, M. (2011) Drugs for diabetes: part 5 DPP-4 inhibitors. British Journal of Cardiology, 18(3), pp. 130-132.
Full text not currently available from Enlighten.
Publisher's URL: http://bjcardio.co.uk/2011/06/drugs-for-diabetes-part-5-dpp-4-inhibitors/
Abstract
The dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral drugs for the treatment of type 2 diabetes. They inhibit the breakdown of glucagon-like peptide-1 (GLP-1) and increase the incretin effect in patients with type 2 diabetes. In clinical practice they are associated with significant reductions in HbA1c, no weight gain and a low risk of hypoglycaemia. Initial cardiovascular safety studies have shown no increase in cardiovascular risk. Indeed, the suggestion of possible cardiovascular benefit seen in the safety studies is now being formally examined in large randomised-controlled trials with primary cardiovascular end points.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | McKay, Dr Gerard |
| Authors: | McDougall, C., McKay, G. A., and Fisher, M. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
| Journal Name: | British Journal of Cardiology |
| Journal Abbr.: | Br J Cardiol |
| Publisher: | MediNews Limited |
| ISSN: | 0969-6113 |
| ISSN (Online): | 1753-4313 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details